A revolutionary, non-invasive way to detect Alzheimer’s disease early
Through a simple eye exam, RetiSpec’s AI-driven retinal imaging identifies neurodegenerative disease markers years before clinical symptoms emerge — affordably, accessibly, and at scale.
Non-invasive screening
Simple eye exam
Clinically validated
Multi-site studies
Featured in
Our Mission
A better future for Alzheimer's starts with the ability to diagnose it
At RetiSpec, we believe a better future for Alzheimer's starts with the ability to diagnose it. Our mission is to enable widespread early and accurate detection of neurodegenerative disease markers with accessible, affordable and scalable AI-driven retinal imaging.
To achieve this vision, we are developing an AI-driven early detection of Alzheimer's, through a simple eye exam.
Why It Matters
Transforming eye care into brain care
Non-Invasive
A quick, comfortable retinal scan using cameras already found in most eye clinics.
Early Detection
Identifies biomarkers years before clinical symptoms emerge.
Clinically Validated
Backed by 7+ peer-reviewed publications and 11+ conference presentations.
Accessible & Scalable
Works with existing retinal cameras in eye clinics.
Our Solution
How it works
Eye Examination
Images captured with existing retinal imaging cameras.
Hyperspectral Imaging
Each pixel captures 100+ color channels instead of 3.
AI-Powered Analysis
Proprietary ML/DL models detect markers years before symptoms.
See It in Action
A case study in community-based settings
Watch how RetiSpec's AI-driven eye test enables early detection of Alzheimer's disease through a simple, non-invasive retinal scan.
Impact
Early detection changes lives
Alzheimer's affects over 55 million people worldwide. Early detection enables earlier intervention.
7+
Peer-reviewed publications
11+
Conference presentations
$10M
Funding raised (USD)
DH50
CB Insights Digital Health
Testimonials
Trusted by leading experts in Alzheimer's research
I am impressed with the potential of their hyperspectral imaging technology to support early diagnosis of Alzheimer’s disease in a manner that is affordable and scalable. The RetiSpec team is innovative, collaborative, and pragmatic.
Dr. Sharon Cohen, MD, FRCPC
Medical Director & Behavioural Neurologist, Toronto Memory Program
We believe that RetiSpec’s retinal scanner stands out and shows promise as a unique diagnostic tool among a range of technologies in development. The technology has the potential to facilitate early diagnosis and save the healthcare system money and resources.
Dr. Howard Fillit, MD
Executive Director & CSO, Alzheimer’s Drug Discovery Foundation
RetiSpec’s retinal imaging technology holds great promise as a rapid, simple-to-administer, non-invasive and less expensive way to predict amyloid build up in the brain.
John Dwyer
Co-Founder; President, Global Alzheimer’s Platform Foundation (GAP)
Ready to learn more?
Whether you're a clinician, researcher, or simply curious, we'd love to connect.